AI assistant
Marksans Pharma Ltd. Capital/Financing Update 2023
62142_rns_2023-03-10_7abca4fe-6b7f-4aee-b8d8-1a243df3b08f.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Date: 10 th March, 2023
BSE Limited Corporate Relation Department Phiroze Jeejeeboi Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404
National Stock Exchange of India Limited Listing Department Exchange Plaza, C-l, Block-G, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051. Symbol: MARKSANS
PRESS RELEASE
Marksans Pharma Limited announces US FDA approval for Famotidine Tablets USP, 10 mg and 20 mg.
Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 524404) hereby announces that it has received final approval from US Food & Drugs Administration for its Abbreviated New Drug Application (ANDA) of Famotidine Tablets USP, 10 mg and 20 mg for over-the-counter (OTC) use.
The product is bioequivalent to the reference listed drug (RLD), Pepcid AC® tablets, a registered trademark of Johnson & Johnson Consumer Inc. which has sales of over \$ 200 million in the US market.
Marksans' OTC Famotidine Tablets USP, 10 mg and 20 mg, are acid reducers which used to treat conditions where reduction of stomach acid is needed, such as acid indigestion, occasional heartburn, or sour stomach from eating or drinking certain foods or beverages.
"We are delighted to continue OTC gastro portfolio expansion for our customers and it will help us to fulfill an important therapy gap created in Antacids market due to Ranitidine withdrawal", says Mr. Mark Saldanha, Managing Director of Marksans Pharma Limited.
For Marksans Pharma Limited
HAN PANIGRAHI Digitally signed by HARSHAVARDHAN PANIGRAHI Date: 2023.03.10 11:31:35 +05'30'
Harshavardhan Panigrahi Company Secretary
About Marksans Pharma Ltd
Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are E-mail: [email protected] HARSHAVARD
www.marksanspharma.com CIN : L2411 OMH1992PLC066364
Marksans Pharma Ltd.
11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 224001 2000 • Fax: +91-224001 2011
approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Antiallergies. The company is marketing these products globally.
Disclaimer:
This press release may include statements concerning our future growth prospects are forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward looking statements. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform. The company undertakes no duty to update forward-looking statements except as required by applicable law.
CIN: L24110MH1992PLC066364 www.marksanspharma.com
"L
Marksans Pharma Ltd.
11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 • Tel.: +91 224001 2000 • Fax: +91-224001 2Q11 . E-mail: [email protected])